News Bayer adds menopause drug to pipeline with KaNDy acquisition Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline.
News UK's KaNDy Therapeutics funds mid-stage trial of HRT 'replac... Biotech hopes for IPO or big pharma deal to fund phase 3
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face